FR2421888A1
(fr)
*
|
1978-02-06 |
1979-11-02 |
Synthelabo |
Amides d'alkylene-diamines et leur application en therapeutique
|
JPS6016948B2
(ja)
*
|
1978-03-29 |
1985-04-30 |
住友化学工業株式会社 |
新規なキナゾリン誘導体及びその製造法
|
US4287341A
(en)
*
|
1979-11-01 |
1981-09-01 |
Pfizer Inc. |
Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
|
EP0022481A1
(en)
*
|
1979-06-21 |
1981-01-21 |
Mitsubishi Yuka Pharmaceutical Co., Ltd. |
5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
|
US4426382A
(en)
*
|
1980-02-13 |
1984-01-17 |
Sankyo Company Limited |
4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
|
US4377581A
(en)
*
|
1980-03-03 |
1983-03-22 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
|
US4351940A
(en)
*
|
1980-03-03 |
1982-09-28 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
|
US4367335A
(en)
*
|
1981-08-03 |
1983-01-04 |
Mead Johnson & Company |
Thiazolidinylalkylene piperazine derivatives
|
DE3304292A1
(de)
*
|
1982-10-11 |
1984-04-12 |
Brown, Boveri & Cie Ag, 6800 Mannheim |
Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock
|
DE3346675A1
(de)
*
|
1983-12-23 |
1985-07-04 |
Beiersdorf Ag, 2000 Hamburg |
Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
|
AT384218B
(de)
*
|
1985-12-04 |
1987-10-12 |
Gerot Pharmazeutika |
Verfahren zur herstellung von neuen chinazolin-derivaten
|
JP2657760B2
(ja)
*
|
1992-07-15 |
1997-09-24 |
小野薬品工業株式会社 |
4−アミノキナゾリン誘導体およびそれを含有する医薬品
|
CA2077252C
(en)
*
|
1992-08-31 |
2001-04-10 |
Khashayar Karimian |
Methods of making ureas and guanidines, and intermediates therefor
|
US20060222647A1
(en)
*
|
1993-05-27 |
2006-10-05 |
Beavo Joseph A |
Methods and compositions for modulating the activity of PDE5
|
US5776962A
(en)
*
|
1994-08-03 |
1998-07-07 |
Cell Pathways, Inc. |
Lactone compounds for treating patient with precancerous lesions
|
US5696159A
(en)
*
|
1994-08-03 |
1997-12-09 |
Cell Pathways, Inc. |
Lactone compounds for treating patients with precancerous lesions
|
US5869486A
(en)
*
|
1995-02-24 |
1999-02-09 |
Ono Pharmaceutical Co., Ltd. |
Fused pyrimidines and pyriazines as pharmaceutical compounds
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6046216A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US20020143007A1
(en)
*
|
1996-02-02 |
2002-10-03 |
Garvey David S. |
Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
|
US5932538A
(en)
*
|
1996-02-02 |
1999-08-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
|
US20050065161A1
(en)
*
|
1996-02-02 |
2005-03-24 |
Nitromed, Inc. |
Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
|
GB9708917D0
(en)
*
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
CA2238283C
(en)
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
|
CN100430396C
(zh)
|
1997-11-12 |
2008-11-05 |
拜耳医药保健股份公司 |
用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6180629B1
(en)
|
1998-08-14 |
2001-01-30 |
Cell Pathways, Inc. |
[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
MXPA03007623A
(es)
*
|
2001-02-26 |
2003-12-04 |
Tanabe Seiyaku Co |
Derivado de piridopirimidina o naftiridina.
|
DE50209015D1
(de)
*
|
2001-05-09 |
2007-02-01 |
Bayer Healthcare Ag |
NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
|
EP1312363A1
(en)
*
|
2001-09-28 |
2003-05-21 |
Pfizer Products Inc. |
Methods of treatment and kits comprising a growth hormone secretagogue
|
US7342884B2
(en)
*
|
2002-03-13 |
2008-03-11 |
Harmonic, Inc. |
Method and apparatus for one directional communications in bidirectional communications channel
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
MXPA04009997A
(es)
*
|
2002-04-12 |
2004-12-13 |
Celgene Corp |
Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
|
MXPA04009996A
(es)
*
|
2002-04-12 |
2005-07-01 |
Celgene Corp |
Metodos para la identificacion de moduladores de la angiogenesis, compuestos descubiertos por los mismos, y metodos de tratamiento usando los compuestos.
|
DE10232113A1
(de)
*
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
KR101223914B1
(ko)
|
2003-11-21 |
2013-01-18 |
어레이 바이오파마 인크. |
Akt 단백질 키나제 억제제
|
DE102005001989A1
(de)
*
|
2005-01-15 |
2006-07-20 |
Bayer Healthcare Ag |
Intravenöse Formulierungen von PDE-Inhibitoren
|
DE102005009241A1
(de)
*
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit kontrollierter Bioverfügbarkeit
|
DE102005009240A1
(de)
*
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
EP1931797A2
(en)
*
|
2005-09-29 |
2008-06-18 |
Bayer HealthCare AG |
Pde inhibitors and combinations thereof for the treatment of urological disorders
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
RU2481336C2
(ru)
*
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
EP2054418B1
(en)
|
2006-07-06 |
2011-11-09 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
CN101711153A
(zh)
*
|
2007-06-13 |
2010-05-19 |
拜耳先灵制药股份公司 |
用于治疗听觉损伤的pde抑制剂
|
NZ582692A
(en)
|
2007-07-05 |
2012-05-25 |
Array Biopharma Inc |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
KR101624361B1
(ko)
*
|
2007-07-05 |
2016-05-25 |
어레이 바이오파마 인크. |
Akt 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
|
ES2422733T3
(es)
*
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
NZ586720A
(en)
*
|
2008-01-09 |
2012-11-30 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
CA2718412A1
(en)
*
|
2008-03-24 |
2009-10-01 |
Celgene Corporation |
Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
CN110433165A
(zh)
|
2011-04-01 |
2019-11-12 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
BR112013025353A8
(pt)
|
2011-04-01 |
2018-01-02 |
Genentech Inc |
combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
|
MX2016014384A
(es)
|
2014-06-23 |
2017-01-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
|
EP3648766A4
(en)
*
|
2017-07-06 |
2021-07-07 |
Case Western Reserve University |
PEPTIDIC AND SMALL MOLECULE AGONISTS OF WPHA AND THEIR USES
|